SIOP 2021 - 53rd Annual Congress of the International Society of Paediatric Oncology
Oct 21 - Oct 24, 2021 | HonoluluHawaii
LARVOL is not affiliated with 53rd Annual Congress of the International Society of Paediatric Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 17 abstracts linked to Trials
[VIRTUAL] LONG TERM OUTCOMES FOR PATIENTS WITH ANAPLASTIC BILATERAL WILMS TUMORS ON AREN0534
[VIRTUAL] LATE TOXICITY COMPARISON OF ALKYLATING-BASED MAINTENANCE WITH CYCLOPHOSPHAMIDE (VAC) VERSUS IFOSFAMIDE (VAI) IN EWING SARCOMA SURVIVORS TREATED IN THE RANDOMIZED CLINICAL TRIAL EURO-EWING99-R1 IN FRANCE
[VIRTUAL] ACADEMIC, PHASE I/II TRIAL ON T CELLS EXPRESSING A THIRD-GENERATION GD2 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE-9 SAFETY SWITCH FOR TREATMENT OF RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA
[VIRTUAL] A PHASE 1/2, OPEN-LABEL STUDY OF REPOTRECTINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ADVANCED OR METASTATIC MALIGNANCIES HARBORING ALK, ROS1, OR NTRK1-3 ALTERATIONS
[VIRTUAL] CIRCULATING TUMOR DNA AS A BIOMARKER IN FAVORABLE HISTOLOGY (FH) WILMS TUMOR (WT) PATIENTS: ANALYSIS FROM CHILDREN'S ONCOLOGY GROUP (COG) TRIAL AREN0533
[VIRTUAL] NAXITAMAB TREATMENT OF REFRACTORY/RELAPSED HIGH-RISK NEUROBLASTOMA (R/R HR NB); SUBGROUP ANALYSIS OF UPDATED INTERIM EFFICACY AND SAFETY DATA FOR THE REGISTRATIONAL PHASE II TRIAL
[VIRTUAL] PREDICTORS OF SEVERE TOXICITY AND POOR EFFICACY OF REINDUCTION CHEMOTHERAPY IN FIRST RELAPSE OF B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) AALL1331
[VIRTUAL] OUTCOME AND PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN INFANTS WITH KMT2A-GERMLINE ACUTE LYMPHOBLASTIC LEUKEMIA TREATED ON THE INTERFANT-06 PROTOCOL.
[VIRTUAL] CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY PERSISTS DESPITE REDUCTION OF VINCRISTINE FREQUENCY IN CHILDREN WITH B-ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM CHILDREN'S ONCOLOGY GROUP AALL0932
[VIRTUAL] A THREE-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMAS (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 SFCE PROTOCOL.
[VIRTUAL] RESULTS FROM AN OPEN-LABEL, PHASE 1/2 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE IN PEDIATRIC PATIENTS WITH ADVANCED STAGE HODGKIN LYMPHOMA
[VIRTUAL] ORAL VINORELBINE EXPOSURE VARIABILITY AMONG PEDIATRIC PATIENTS: POTENTIAL ROLE OF ABCB1, ABCG2, AND UGT2B7 GENETIC VARIANTS.
[VIRTUAL] PHASE II TRIAL OF ORAL VINORELBINE IN CHILDREN WITH PROGRESSIVE OR RECURRENT UNRESECTABLE LOW-GRADE GLIOMA
[VIRTUAL] WHAT DOES A NON-RESPONSE TO INDUCTION CHEMOTHERAPY IMPLY IN HIGH-RISK MEDULLOBLASTOMAS?
[VIRTUAL] LONG-TERM OUTCOMES FOR CHILDREN WITH ATRT TREATED WITH INTENSIVE MULTIMODAL THERAPY: AN UPDATE ON DFCI #02-294